Feb 15, 2017 03:30 PM IST | Source: Moneycontrol.com
Buy Cipla; target of Rs 740: Centrum
Centrum is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 740 in its research report dated February 08, 2017.
Centrum's research report on Cipla
The acquired Invagen and Exelan in the US are well-integrated with Cipla. The launch of Sereflo inhaler in UK is a positive step. The expected good growth in the domestic market, with leadership position in respiratory, oncology and ARV segments would drive future growth.
We maintain our Buy rating on Cipla, with a TP of Rs 740 (earlier Rs610) based on 24x March’19E EPS of Rs 30.7. Cipla’s Q3FY17 results were in-line with our expectations. A slew of positive factors led to a 16% YoY growth in the company’s revenues, 390bps rise in margin to 18.6% and 44% growth in net profit.
For all recommendations, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.